简体中文 | 繁體中文 | English

Health and Pharmaceutical Press Releases

2024-07-11 14:19 Viromed Medical AG Seeks Special Approval for Cold Plasma Device for the Prevention of Ventilator-Associated Pneumonia (VAP)
2024-07-11 12:50 Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics
2024-07-10 13:03 MMI Builds Global Momentum with Multiple Distribution Agreements and Regulatory Approvals
2024-07-08 17:51 Nominations Open for the Prestigious Tu Youyou Award 2024
2024-07-05 11:26 ABE Technology Introduces AI-Enhanced Cardiac Imaging System 'CardioVision'
2024-07-04 13:20 Enhancing Technologist Experience and Patient Workflow, Carestream Reveals New Enhancements to CARESTREAM DRX-Evolution Plus System and ImageView Software
2024-07-04 11:40 Delta-Fly Pharma Inc.: Notice of initiation of patients enrollment in Phase III Pivotal comparative clinical trial of DFP-14323
2024-07-02 10:25 Swedish Match USA, Inc. Presents to U.S. Food and Drug Administration Advisory Committee to Renew Modified Risk Claim for General Snus
2024-07-01 16:50 TauRx Submits UK Marketing Authorisation Application for HMTM as a Treatment for Alzheimer’s Disease
2024-06-28 12:03 Medisca Opens New Pharmaceutical Repackaging Facility to Meet Global Demands in Personalized Medicine
2024-06-28 10:54 QPS Announces New Laboratory Services for Clinical Trials and Cell Therapy Development
2024-06-27 16:32 Takeda Announces New Assignments of Directors
2024-06-26 10:31 Kenvue Releases Inaugural Healthy Lives Mission Report
2024-06-26 09:37 RoslinCT Appoints Professor Sir Peter Mathieson and Alexander Vos as New Non-Executive Directors
2024-06-26 09:34 Technology Holdings advises Design + Industry, a leading MedTech Product Design and Engineering consultancy, on its strategic sale to Capgemini
2024-06-25 10:58 Merck Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer
2024-06-24 15:05 Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
2024-06-24 11:26 Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
2024-06-22 09:24 QPS Announces New Global Clinical Research Operations Leadership
2024-06-21 15:35 C3i Center Inc is First CDMO in Canada to Receive Approval for a Drug Establishment License to Commercially Produce Cell Therapy Drug Products

Business Wire Weibo

Press Releases

Latest Releases